Background: There are few validated fluid biomarkers in FTD. Glial fibrillary acidic protein (GFAP) is a measure of astrogliosis, a known pathological process of FTD, but has yet to be explored as potential biomarker.
INTRODUCTION
Frontotemporal dementia (FTD) is a progressive neurodegenerative condition with around a third of cases caused by an autosomal dominant gene mutation in progranulin (GRN), chromosome 9 open reading frame 72 (C9orf72) or microtubule-associated protein tau (MAPT) 1 . As clinical trials in genetic FTD are fast approaching, robust biomarkers that allow accurate measurement of disease onset and progression are becoming increasingly important. In particular, many trials will focus on the presymptomatic stage of disease where neuropathological alterations are already present 2 and yet few biomarkers have been shown to be abnormal in this phase [3] [4] [5] .
Cerebrospinal fluid (CSF) or plasma/serum progranulin levels in GRN mutation carriers 4, 6 and CSF (poly)GP dipeptide repeat concentrations in C9orf72 expansion carriers 5, 7, 8 are markers of specific protein abnormalities in genetic FTD but both are abnormal from early in the presymptomatic period (and potentially from birth). In contrast, neurofilament light chain (NfL) is a marker of neuronal death and axonal degeneration (measurable in CSF 3, 9, 10 as well as both plasma 11 and serum 12, 13 ) that is not specific to FTD 14 and has only been shown to be abnormal in the very late presymptomatic period prior to conversion to the symptomatic phase 3 . Glial fibrillary acidic protein (GFAP) is a marker of astrogliosis, the abnormal proliferation of astrocytes due to neuronal damage 15 , and has previously been shown to be increased in frontal cortical tissue in FTD 16 , and raised in both the CSF and serum of patients with symptomatic FTD [17] [18] [19] . However, it has yet to be explored using ultrasensitive bloodbased assays in genetic FTD mutation carriers.
In this study, we aimed to investigate within the Genetic FTD Initiative (GENFI) cohort whether plasma GFAP was abnormal in each of the different genetic FTD groups during the symptomatic period, and whether we could detect any presymptomatic changes. We also aimed to explore the relationship of GFAP with plasma NfL and with cognitive and neuroimaging measures.
METHODS

Participants
Participants were recruited from GENFI, a natural history study of genetic FTD involving 23 research centres across Europe and Canada (www.genfi.org.uk) 2 involving symptomatic carriers of mutations in GRN, MAPT, or C9orf72, and those at risk of carrying a mutation because a first-degree relative was a known symptomatic carrier. 469 consecutively recruited individuals from the GENFI study were included: 114 C9orf72 expansion carriers (74 presymptomatic, 40 symptomatic), 119 GRN mutation carriers (88 presymptomatic, 31 symptomatic), 53 MAPT mutation carriers (34 presymptomatic, 19 symptomatic) and 183 non-carriers who acted as a control group. Demographic information is shown in Table 1 : age and sex differed significantly between groups. All people in the study underwent a clinical assessment consisting of a medical history with the participant and informant, and physical examination, with symptomatic status diagnosed by a clinician who was an expert in the FTD field [20] [21] [22] [23] [24] specific diagnoses are shown in Table 1 . All participants underwent a standardized examination including the Mini-Mental State Examination (MMSE) and the Frontotemporal Lobar Degeneration Clinical Dementia Rating scale (FTLD-CDR) 25 . Participants also performed 3D T1-weighted magnetic resonance imaging (MRI) of the brain: 432 scans were available for cross-sectional analysis, of which a subgroup of 243 participants had a follow-up scan (on the same scanner) for analysis [mean (standard deviation) interval 1.12 (0.29) years between baseline and follow-up]. Volumetric measures of whole brain and cortical regions were calculated using a previously described method that uses the geodesic information flow (GIF) algorithm, which is based on atlas propagation and label fusion (Supplementary Table 1 ) 3, 26 . An annualized longitudinal rate of atrophy was found by calculating the difference in each specific measure between the baseline and longitudinal scan and expressing it as a percentage of the baseline volume over one year (Supplementary Table 2 ). Local ethics committees at each site approved the study and all participants provided written informed consent at enrolment. 
Measurement of plasma markers
Plasma was collected, processed and stored in aliquots at -80°C according to standardised procedures. Samples were measured using the multiplex Neurology 4-Plex A kit (102153, Quanterix
Corporation, Lexington, USA) on the SIMOA HD-1 Analyzer following manufacturer's instructions.
The lower limit of detection of the assay for GFAP and NfL were 0.221 pg/mL and 0.104 pg/mL respectively. Measurements were carried out at the same study site on consecutive days and the operator was blinded to all clinical information, including genetic status. To keep sample processing and plating consistent, plasma samples were thawed at room temperature for two hours and subsequently centrifuged at 10,000g for five minutes. 150µL samples were aliquoted in a 96-well plate (Quanterix Corporation, Lexington, USA) and frozen at -80°C until analysis. Quality control (QC) samples had a mean intra-assay and inter-assay coefficient of variation (CV) of less than 10%.
Statistical analysis
Fisher's exact test was used to compare sex frequencies between groups. Distributions for demographic and biomarker data were investigated graphically using histograms and quantilequantile plots and tested for normality using the Shapiro-Wilk test. As demographic data did not follow a normal distribution, group differences for age at sample collection and FTLD-CDR-SOB were compared using the Kruskal-Wallis test. A linear regression adjusting for age was used to compare MMSE scores between groups. The primary analysis in the study was to investigate whether there were any differences in plasma GFAP concentration from controls in the different genetic mutation groups both symptomatically and presymptomatically, as well as between genetic groups. As biomarker values were not normally distributed, group means were compared by performing a linear mixed regression model with 95% bias-corrected bootstrapped confidence intervals with 2000 repetitions in STATA (v.14; Texas, USA), adjusting for age and sex with family membership included as a random effect. Diagnostic performance of GFAP was assessed by areas under the curve (AUC) obtained by receiver operating characteristic (ROC) analyses, with optimal cut-off levels at the highest Youden's index (sensitivity + specificity -1) using GraphPad Prism V.6 (GraphPad Software, San Diego, California, USA). In order to investigate the relationship of GFAP concentration to demographic, cognitive and imaging measures as well as NfL concentrations, Spearman's correlation coefficient was used. Figure 1 ).
RESULTS
Plasma GFAP concentration
In the presymptomatic groups, concentrations were not significantly increased in any of the groups Tables 1 and 2 ). There were also no differences across the presymptomatic groups.
Comparing symptomatic and presymptomatic carriers, a significantly higher concentration was also seen in the symptomatic versus the presymptomatic GRN mutation carriers (178.1, 114.3-365.2), but not in the other groups (Figure 1 , Tables 1 and 2) . 
Correlation with plasma NfL
Plasma NfL was increased in all three symptomatic groups compared with controls ( Figure 1 , Tables   1 and 3 (Figure 1 , Tables 1 and 3 ). Comparing symptomatic and presymptomatic carriers, a significantly higher concentration was also seen in the symptomatic versus the presymptomatic mutation carriers in each of the groups (Figure 1 , Tables 1 and 3 r=0.76, p<0.001). Table 3 ). No significant correlations were seen in the presymptomatic MAPT mutation carrier group or any of the symptomatic genetic groups.
Table 3. Adjusted mean differences in plasma NfL concentrations between groups with 95% bias-corrected bootstrap confidence intervals. Significant differences in bold
Correlation with cross-sectional imaging data
A significant negative correlation was seen between GFAP concentrations and both GRN and
Correlation with longitudinal imaging data
No significant positive correlation of GFAP concentration with longitudinal rates of atrophy were seen in any of the groups except for in the temporal cortex of symptomatic GRN mutation carriers (r=0.66, p=0.010) ( Supplementary Table 4 ). However, within the same symptomatic GRN group there was also a trend in relationship between GFAP concentration and atrophy rates in the cingulate cortex (r=0.55, p=0.052).
DISCUSSION
In this study, we found that plasma GFAP concentration was significantly increased in genetic FTD but only in GRN mutation carriers, and not in those with C9orf72 expansions or mutations in the MAPT gene. In the presymptomatic period, higher concentrations were correlated with a lower cognitive score (MMSE) and lower brain volumes (in regions characteristically affected in FTD), potentially suggesting GFAP is increased in the late presymptomatic period. In the symptomatic period, higher concentrations were associated with faster rates of atrophy, suggesting GFAP levels are associated with disease intensity, and therefore progression and survival.
GFAP is a major constituent of the astrocytic cytoskeleton and its expression pattern is highly brainenriched 27 . Its levels increase following acute damage to astrocytes such as after a stroke 28 or traumatic brain injury 29 , but also in relation to more chronic insults, such as in neurodegeneration, when astrocytes become reactive, increasing in size and proliferating, a process called astrogliosis 27 . In neurodegeneration, increased GFAP concentrations in biofluid have been reported in Alzheimer's disease 30 (in both CSF 17, 19 and serum 19 ) and amyotrophic lateral sclerosis 18 . Previous studies in FTD have found increased CSF concentrations in symptomatic patients within combined clinical 17, 19 and genetic cohorts 18 but have not previously found changes in blood 19 , nor investigated individual genetic groups previously. Our results suggest that there are differential increases within FTD, with concentrations being higher in people with GRN mutations than in other groups. GRN encodes the progranulin protein, which is a secreted growth factor and known to be involved in many biological processes including inflammation, wound healing and cell proliferation 31, 32 . However, progranulin is also taken up by astrocytes for storage or transportation to the lysosomal compartment [33] [34] [35] , and studies of GRN-deficient mice have shown the presence of astrogliosis [35] [36] [37] . In vitro, progranulin seems to have a role of inactivating astrocytes with evidence that progranulin attenuates a pro-inflammatory phenotype of astrocytes 35 . This suggests that deficiency of progranulin in GRN mutation carriers, may lead to activation of pro-inflammatory phenotypes of astrocytes and subsequent astrogliosis, with increased levels of GFAP protein expression. People with GRN mutations have evidence of astrogliosis pathologically, including within areas of white matter damage 38 (visible in a proportion of people in vivo as white matter hyperintensities on MR imaging, which have been previously shown to be unique to GRN mutations within familial FTD 39 ). Such damage increases as the neurodegeneration progresses 39 , consistent with the pattern of increased plasma GFAP in our study.
In contrast, levels were not increased in plasma in individuals with C9orf72 expansions or MAPT mutations. Whilst astrogliosis is seen in animal models and at postmortem in both C9orf72 40 -and MAPT 41,42 -related FTD, this may well be a late feature of the disease, or the extent of astrogliosis may be less. Future work will be required to investigate this further.
It is well established that multiple biomarkers of neurodegeneration increase in concentration with age, attributed to the reduction of neural integrity in the ageing brain 43 . CSF GFAP concentrations have previously been shown to increase as one gets older 44 , with multiple studies showing proliferation of astrocytes, increased GFAP immunoreactivity, and elevated levels of GFAP mRNA with age [45] [46] [47] [48] [49] . Consistent with this, we also found a significant positive correlation of plasma GFAP concentration with age in the majority of the groups. This highlights the importance of adjusting plasma GFAP concentrations for age in statistical analyses: symptomatic mutation carriers in the C9orf72 and MAPT groups (as well as the GRN group) in this study showed increased levels of plasma GFAP compared to controls and their presymptomatic counterparts, but significance was lost once adjusting for age.
NfL, part of the axonal cytoskeleton, is released following cellular damage. A previous study has shown that NfL concentrations are increased in both the CSF and blood of symptomatic genetic FTD in all three mutation groups, C9orf72, GRN and MAPT 3 . The results in this study replicate these findings in plasma, although we also found elevated levels in presymptomatic C9orf72 mutation carriers. In this latter group, NfL concentrations correlated negatively with MMSE (r=-0.33, p=0.004: Supplementary Table 5 ) and with brain volumes (whole brain, r=-0.53, p<0.001 and cortical regions:
frontal, -0.51, <0.001; temporal, -0.37, 0.001; parietal, -0.51, <0.001; occipital, -0.33, 0.005; cingulate, -0.49, <0.001; insula, -0.47, <0.001: Supplementary Tables 6 and 7 ), suggesting that NfL increases particularly towards the end of the presymptomatic period with increasing neurodegeneration.
Although GRN NfL concentration was not significantly increased presymptomatically, a similar pattern of negative correlation with brain volumes was seen in this group (in whole brain and all cortical regions except the occipital lobe, r=-0.30 to -0.48, p≤0.006). NfL and GFAP concentrations were significantly correlated in all groups including controls, although the correlation coefficient varied from 0.38 to 0.76. A similar correlation has been shown in CSF previously 44 . As both increase with age (Supplementary Table 8 for NfL correlations with age), the correlation is not unexpected, but other unexplained factors are likely to affect the different patterns within genetic FTD; interestingly, the lowest correlation (r=0.38) was in the symptomatic GRN mutation carriers, suggesting that in this group astrogliosis and neurodegeneration are not so closely related.
Correlation of GFAP concentration with cognitive and imaging measures revealed a negative correlation i.e. higher concentration with a lower cognitive score and lower cross-sectional brain volumes in FTD-related regions in presymptomatic GRN mutation carriers. This suggests that GFAP levels start to increase as the brain starts to decrease in volume, and as cognition starts to become affected thus in the later stages of the presymptomatic period in proximity to symptom onset. This would be an important biomarker for GRN-related FTD, as an increase in concentration from baseline during the presymptomatic period would identify a time around the onset of neurodegeneration, and potentially a time when therapeutic intervention may be optimal. Despite the lack of a significant increase in concentration in C9orf72 mutation carriers, a similar pattern of negative correlation with cognition and brain imaging was seen in the presymptomatic period -it would be useful in future studies to investigate the subset of C9orf72 expansion carriers that have increased GFAP concentrations, and how they differ from those with a lower concentration. In particular, it would be helpful to compare carriers with and without concomitant ALS. We also assessed whether GFAP correlated with the rate of brain atrophy measured with longitudinal brain imaging and found a significant positive correlation only in the symptomatic GRN carriers (in the temporal lobe),
implicating an association of GFAP levels with the intensity of the disease process i.e. how fast the disease is progressing. With longitudinal follow-up of participants, it would therefore be hypothesized that higher GFAP concentration would be associated with shorter survival in GRNrelated FTD.
Whilst the multicentre nature of the GENFI study allows collection of samples from a large genetic cohort of FTD worldwide, there remains a relatively small number of cases in each group (leading to low statistical power to detect differences), particularly in the symptomatic carriers, and replication in a larger dataset would be helpful. Due to the nature of the disease process, the mean age of the controls overall is lower compared to the symptomatic mutation carriers, but nonetheless the same results are found whether performing an age-adjusted comparison (as presented above) or when symptomatic mutation carriers are compared with an age-and gender-matched subset of older controls (see Supplementary Figure 2 ). The advantage of studying levels in plasma is that blood is more easily accessible and a relatively cost-efficient way to access bodily fluids in comparison to performing a lumbar puncture; in this study, the use of the ultrasensitive Simoa assay allowed detection at a level in blood that other assays do not. However, it will be important to study CSF levels in more detail in this group, as concentrations can differ between blood and CSF 18 . Lastly, despite significant differences between the groups, there is a substantial overlap in concentrations between carriers and controls: longitudinal study of GFAP concentration over time, particularly in participants that convert from presymptomatic to symptomatic status, will therefore be important to truly evaluate whether changes do occur towards the end of the presymptomatic period and how levels change with progression of disease.
In summary, plasma GFAP levels appear to be uniquely increased in GRN mutation carriers in the current study, and importantly, concentrations may well be abnormal during the late presymptomatic period, suggesting that GFAP might act as marker of proximity to symptom onset.
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Figure 2. Correlation between plasma GFAP concentrations (pg/mL) and age: a)
presymptomatic, and b) symptomatic mutation carriers.
